Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant
Abstract For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting i...
Saved in:
Main Authors: | Scott Thomas, Elysia Roche, Pujan Desai, Nela Pawlowska, Diana Bauer, David Gingrich, Emily Hsu, Amelia N. Deitchman, Fran Aweeka, Pamela N. Munster |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-024-77186-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance
by: Juliane Albrecht, et al.
Published: (2025-01-01) -
Stent Fracture after Everolimus-Eluting Stent Implantation
by: Ali S. Almasood, et al.
Published: (2011-01-01) -
Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis
by: Yitian Lang, et al.
Published: (2025-01-01) -
Elution Adsorption Dynamics of Organic Substances on Carbon Adsorbents
by: N.S. Polyakov, et al.
Published: (1993-03-01) -
Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
by: Jianli Zhao, et al.
Published: (2025-01-01)